Imaging and Dosing in Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)

Stewart M. Spies*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation chelator tiuxetan, which attaches the high-energy pure β emitter 90Y, for therapy, or the γ emitter indium 111, for imaging. The biodistribution of the therapeutic dose of 90Y ibritumomab tiuxetan can be predicted by using an imaging dose of the antibody labeled with 111In. Calculation of the therapeutic dose is simple and is based on patient weight and baseline platelet count: for patients with a platelet count of 150 × 109/L or greater the dose of is 0.4 mCi/kg; for patients with mild thrombocytopenia (platelet count 100 × 109/L to 149 × 109/L) the dose is reduced to 0.3 mCi/kg; and the total dose should not exceed 32 mCi. Patients with platelet counts of less than 100 × 109/L should not be treated with 90Y ibritumomab tiuxetan. Imaging with 111In ibritumomab tiuxetan is performed only to assess biodistribution of the radioimmunoconjugate. Uptake in sites of pathologic adenopathy, as well as other areas of lymphomatous involvement, is frequently seen on the images, but visualization of tumor uptake is not required to proceed with the therapeutic dose of 90Y ibritumomab tiuxetan.

Original languageEnglish (US)
Pages (from-to)10-13
Number of pages4
JournalSeminars in Nuclear Medicine
Volume34
Issue number1 SUPPL.1
DOIs
StatePublished - Jan 2004

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Imaging and Dosing in Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)'. Together they form a unique fingerprint.

Cite this